{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:19:26Z","timestamp":1791821966334,"version":"4.3.4"},"reference-count":33,"publisher":"Royal College of Psychiatrists","issue":"5","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["BJPsych open"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec id=\"S2056472421009698_sec_a1\"><jats:title>Background<\/jats:title><jats:p>Risk of death from suicide in Huntington's disease is notably elevated relative to that in the general population, although the incidence within HD populations has not been precisely defined. Robust incidence estimates of suicidal behavior can serve as references for HD therapeutic research and post-marketing surveillance to help evaluate the suicidality risk of novel therapeutics.<\/jats:p><\/jats:sec><jats:sec id=\"S2056472421009698_sec_a2\"><jats:title>Aims<\/jats:title><jats:p>To estimate the incidence rate of completed suicide and suicide attempt in the global, prospective HD cohort study Enroll-HD that records these events per protocol.<\/jats:p><\/jats:sec><jats:sec id=\"S2056472421009698_sec_a3\" sec-type=\"methods\"><jats:title>Method<\/jats:title><jats:p>A total of 20 912 participants were available for analysis (HD gene-expansion carriers (HDGECs)<jats:italic>n<\/jats:italic>= 15 924; non-HDGECs n = 4988) representing a collective observation period of 53 390 participant-years. Each observed event was subject to clinical review and evaluation. We generated incidence rates (events per 100 000 person-years) for suicides and suicide attempts using all available data, as well as by year of study and geographical region. Proportionate mortality statistics for suicide and respective 95% confidence intervals were also generated.<\/jats:p><\/jats:sec><jats:sec id=\"S2056472421009698_sec_a4\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>The overall incidence rate of suicide in HDGECs was 72 per 100 000 person-years, and 8 per 100 000 person-years in non-HDGECs. Proportionate mortality attributable to suicide in HDGECs was 4.6%. For suicide attempts, the global overall incidence rate observed in HDGECs was 306\u2013375 per 100 000 person-years, and 23\u201338 per 100 000 person-years in non-HDGECs.<\/jats:p><\/jats:sec><jats:sec id=\"S2056472421009698_sec_a5\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>The incidence estimates calculated here can be used as a reference to help evaluate drug safety and may also be useful in assessing progress in clinical care for HDGECs once therapeutic interventions become widely available.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjo.2021.969","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T08:37:54Z","timestamp":1630399074000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":17,"title":["Incidence of completed suicide and suicide attempts in a global prospective study of Huntington's disease"],"prefix":"10.1192","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2469-6252","authenticated-orcid":false,"given":"Erik","family":"van Duijn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Raquel","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Neacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"S2056472421009698_ref11","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"S2056472421009698_ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.31232"},{"key":"S2056472421009698_ref1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12502"},{"key":"S2056472421009698_ref12","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-130071"},{"key":"S2056472421009698_ref19","doi-asserted-by":"publisher","DOI":"10.1080\/00949650701749356"},{"key":"S2056472421009698_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2011.10.031"},{"key":"S2056472421009698_ref13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1212\/WNL.0000000000006999","article-title":"Reader response: evaluating depression and suicidality in tetrabenazine users with Huntington disease","volume":"92","author":"Sampaio","year":"2019","journal-title":"Neurology"},{"key":"S2056472421009698_ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.21834"},{"key":"S2056472421009698_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00234-2"},{"key":"S2056472421009698_ref29","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.29.12.911"},{"key":"S2056472421009698_ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000327754"},{"key":"S2056472421009698_ref30","unstructured":"30 Statistics Netherlands. Ranglijst doodsoorzaken op basis van sterfte. [Ranking of Causes of Death Based on Mortality.] National Institute for Health and Environment, 2019 (https:\/\/www.volksgezondheidenzorg.info\/ranglijst\/ranglijst-doodsoorzaken-op-basis-van-sterfte)."},{"key":"S2056472421009698_ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.06.001"},{"key":"S2056472421009698_ref17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"S2056472421009698_ref27","unstructured":"27 World Health Organization (WHO). Global Health Observatory Data: Suicide Rates, 2016. WHO, 2016 (https:\/\/www.who.int\/gho\/mental_health\/suicide_rates\/en\/)."},{"key":"S2056472421009698_ref14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005817"},{"key":"S2056472421009698_ref21","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04967blu"},{"key":"S2056472421009698_ref9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-307343"},{"key":"S2056472421009698_ref16","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12388"},{"key":"S2056472421009698_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.03.043"},{"key":"S2056472421009698_ref3","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-170270"},{"key":"S2056472421009698_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.11.074"},{"key":"S2056472421009698_ref20","unstructured":"20 Center for Drug Evaluation and Research. Guidance for Industry: Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials. US Food and Drug Administration, 2012 (https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-suicidal-ideation-and-behavior-prospective-assessment-occurrence-clinical-trials)."},{"key":"S2056472421009698_ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.667420"},{"key":"S2056472421009698_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60111-1"},{"key":"S2056472421009698_ref22","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-160206"},{"key":"S2056472421009698_ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9013-6"},{"key":"S2056472421009698_ref25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007244"},{"key":"S2056472421009698_ref28","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz1568"},{"key":"S2056472421009698_ref32","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2017.0268"},{"key":"S2056472421009698_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2015.12.018"},{"key":"S2056472421009698_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30391-0"},{"key":"S2056472421009698_ref33","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-clinpsy-021815-093204"}],"container-title":["BJPsych Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2056472421009698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T01:48:05Z","timestamp":1699408085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2056472421009698\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["S2056472421009698"],"URL":"https:\/\/doi.org\/10.1192\/bjo.2021.969","relation":{},"ISSN":["2056-4724"],"issn-type":[{"value":"2056-4724","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2021. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e158"}}